Cogent Biosciences   Report issue

For profit Phase 1 Phase 3
Founded: Cambridge MA United States (2014)

Organization Overview

First Clinical Trial
2016
NCT02776813
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Cogent Biosciences | Cogent Biosciences, Inc. | Unum Therapeutics Inc.

Active Ingredients

Drugs in Phase 3 Trials (2)

plx9486 (3 trials)

sunitinib (sutent) (1 trial)

Drugs in Phase 1 Trials (5)

actr087 (3 trials)

actr707 (1 trial)

rituximab (rituxan) (1 trial)

sea-bcma (1 trial)

trastuzumab (herceptin) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Lymphoma (Phase 1)

Lymphoma, B-Cell (Phase 1)

Multiple Myeloma (Phase 1)

Neoplasms, Plasma Cell (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 7
  • # of Trial APIs: 7